Osler, Hoskin & Harcourt LLP advised Simmunome on the round. On September 18, 2023, Simmunome announced it secured $2 million in a pre-seed funding round led...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Inversago Pharma on the matter. On August 10, 2023, Inversago Pharma announced its business combination with Nova Nordisk for US$1.075...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Deep Sky in the transaction. Deep Sky secured $10 million of funding from Investissement Québec and Brightspark Ventures. The company...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Blockstream on the matter. Blockstream raised US$125 million in a convertible notes and secure loan financing. The convertible note was...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Round13 E-Fund, L.P. on the round. On November 18, 2022, Alvéole announced it had closed its $8.1 million Series A...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Acerta Analytics Solutions on the financing. On November 22, 2022, Acerta announced it had secured $10.4 million in a Series...
You must be a Standard 1 Year member to access this content.
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised Interaxon on the round. On August 11, 2022, Interaxon announced it had closed its US$9.5 million Series C financing round...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP advised BrainBox AI on the round. On October 28, 2021, BrainBox AI completed its US$24 million Series A financing round led...
You must be a Standard 1 Year member to access this content.
